Patient-derived tumour xenografts as models for oncology drug development

John J. Tentler, Aik-Choon Tan, Colin D. Weekes, Antonio Jimeno, Stephen Leong, Todd M. Pitts, John J. Arcaroli, Wells A. Messersmith, S. Gail Eckhardt

Research output: Contribution to journalArticle

618 Citations (Scopus)

Abstract

Progress in oncology drug development has been hampered by a lack of preclinical models that reliably predict clinical activity of novel compounds in cancer patients. In an effort to address these shortcomings, there has been a recent increase in the use of patient-derived tumour xenografts (PDTX) engrafted into immune-compromised rodents such as athymic nude or NOD/SCID mice for preclinical modelling. Numerous tumour-specific PDTX models have been established and, importantly, they are biologically stable when passaged in mice in terms of global gene-expression patterns, mutational status, metastatic potential, drug responsiveness and tumour architecture. These characteristics might provide significant improvements over standard cell-line xenograft models. This Review will discuss specific PDTX disease examples illustrating an overview of the opportunities and limitations of these models in cancer drug development, and describe concepts regarding predictive biomarker development and future applications.

Original languageEnglish
Pages (from-to)338-350
Number of pages13
JournalNature Reviews Clinical Oncology
Volume9
Issue number6
DOIs
Publication statusPublished - 2012 Jun 1
Externally publishedYes

Fingerprint

Heterografts
Pharmaceutical Preparations
Neoplasms
Inbred NOD Mouse
SCID Mice
Rodentia
Biomarkers
Gene Expression
Cell Line

ASJC Scopus subject areas

  • Oncology

Cite this

Tentler, J. J., Tan, A-C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., ... Eckhardt, S. G. (2012). Patient-derived tumour xenografts as models for oncology drug development. Nature Reviews Clinical Oncology, 9(6), 338-350. https://doi.org/10.1038/nrclinonc.2012.61

Patient-derived tumour xenografts as models for oncology drug development. / Tentler, John J.; Tan, Aik-Choon; Weekes, Colin D.; Jimeno, Antonio; Leong, Stephen; Pitts, Todd M.; Arcaroli, John J.; Messersmith, Wells A.; Eckhardt, S. Gail.

In: Nature Reviews Clinical Oncology, Vol. 9, No. 6, 01.06.2012, p. 338-350.

Research output: Contribution to journalArticle

Tentler, JJ, Tan, A-C, Weekes, CD, Jimeno, A, Leong, S, Pitts, TM, Arcaroli, JJ, Messersmith, WA & Eckhardt, SG 2012, 'Patient-derived tumour xenografts as models for oncology drug development', Nature Reviews Clinical Oncology, vol. 9, no. 6, pp. 338-350. https://doi.org/10.1038/nrclinonc.2012.61
Tentler, John J. ; Tan, Aik-Choon ; Weekes, Colin D. ; Jimeno, Antonio ; Leong, Stephen ; Pitts, Todd M. ; Arcaroli, John J. ; Messersmith, Wells A. ; Eckhardt, S. Gail. / Patient-derived tumour xenografts as models for oncology drug development. In: Nature Reviews Clinical Oncology. 2012 ; Vol. 9, No. 6. pp. 338-350.
@article{46410c7e606a4963bb79f2b0d37e3864,
title = "Patient-derived tumour xenografts as models for oncology drug development",
abstract = "Progress in oncology drug development has been hampered by a lack of preclinical models that reliably predict clinical activity of novel compounds in cancer patients. In an effort to address these shortcomings, there has been a recent increase in the use of patient-derived tumour xenografts (PDTX) engrafted into immune-compromised rodents such as athymic nude or NOD/SCID mice for preclinical modelling. Numerous tumour-specific PDTX models have been established and, importantly, they are biologically stable when passaged in mice in terms of global gene-expression patterns, mutational status, metastatic potential, drug responsiveness and tumour architecture. These characteristics might provide significant improvements over standard cell-line xenograft models. This Review will discuss specific PDTX disease examples illustrating an overview of the opportunities and limitations of these models in cancer drug development, and describe concepts regarding predictive biomarker development and future applications.",
author = "Tentler, {John J.} and Aik-Choon Tan and Weekes, {Colin D.} and Antonio Jimeno and Stephen Leong and Pitts, {Todd M.} and Arcaroli, {John J.} and Messersmith, {Wells A.} and Eckhardt, {S. Gail}",
year = "2012",
month = "6",
day = "1",
doi = "10.1038/nrclinonc.2012.61",
language = "English",
volume = "9",
pages = "338--350",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Patient-derived tumour xenografts as models for oncology drug development

AU - Tentler, John J.

AU - Tan, Aik-Choon

AU - Weekes, Colin D.

AU - Jimeno, Antonio

AU - Leong, Stephen

AU - Pitts, Todd M.

AU - Arcaroli, John J.

AU - Messersmith, Wells A.

AU - Eckhardt, S. Gail

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Progress in oncology drug development has been hampered by a lack of preclinical models that reliably predict clinical activity of novel compounds in cancer patients. In an effort to address these shortcomings, there has been a recent increase in the use of patient-derived tumour xenografts (PDTX) engrafted into immune-compromised rodents such as athymic nude or NOD/SCID mice for preclinical modelling. Numerous tumour-specific PDTX models have been established and, importantly, they are biologically stable when passaged in mice in terms of global gene-expression patterns, mutational status, metastatic potential, drug responsiveness and tumour architecture. These characteristics might provide significant improvements over standard cell-line xenograft models. This Review will discuss specific PDTX disease examples illustrating an overview of the opportunities and limitations of these models in cancer drug development, and describe concepts regarding predictive biomarker development and future applications.

AB - Progress in oncology drug development has been hampered by a lack of preclinical models that reliably predict clinical activity of novel compounds in cancer patients. In an effort to address these shortcomings, there has been a recent increase in the use of patient-derived tumour xenografts (PDTX) engrafted into immune-compromised rodents such as athymic nude or NOD/SCID mice for preclinical modelling. Numerous tumour-specific PDTX models have been established and, importantly, they are biologically stable when passaged in mice in terms of global gene-expression patterns, mutational status, metastatic potential, drug responsiveness and tumour architecture. These characteristics might provide significant improvements over standard cell-line xenograft models. This Review will discuss specific PDTX disease examples illustrating an overview of the opportunities and limitations of these models in cancer drug development, and describe concepts regarding predictive biomarker development and future applications.

UR - http://www.scopus.com/inward/record.url?scp=84861719757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861719757&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2012.61

DO - 10.1038/nrclinonc.2012.61

M3 - Article

C2 - 22508028

AN - SCOPUS:84861719757

VL - 9

SP - 338

EP - 350

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 6

ER -